

The Brazilian Journal of INFECTIOUS DISEASES



www.elsevier.com/locate/bjid

Original article

HIV-infected youths transitioning from pediatric to adult outpatient care in a teaching tertiary care hospital in São Paulo city, Brazil



Angela Carvalho Freitas • a,*, Vivian Iida Avelino-Silvaa, Eliana Battaggia Gutierrezb, Heloisa Helena de Souza Marquesc, Giuliana Stravinskas Durigonc, Aluisio Cotrim Seguradoa

- a Universidade de São Paulo, Faculdade de Medicina, Departamento de Molestias Infecciosas e Parasitárias, São Paulo, SP, Brazil
- b Serviço de Atendimento Especializado em DST e AIDS, Secretaria de Saúde da Prefeitura do Município de São Paulo, São Paulo, SP, Brazil
- ^c Universidade de São Paulo, Faculdade de Medicina, Instituto da Criança, São Paulo, SP, Brazil

ARTICLE INFO

Article history: Received 11 August 2018 Accepted 21 July 2019 Available online 31 August 2019

Keywords:
Adolescent
Young adult
Pediatric HIV
Transition-to-care
Adult care

ABSTRACT

Background: HIV-infected children surviving until adulthood have been transitioning to adult outpatient health care service in Brazil since the late 2000's. Deterioration of clinical condition is expected during this period, as reported among youths with non-communicable chronic diseases. Despite their young age, they are long-term hosts of the virus, have prolonged exposure to antiretroviral therapy and have suffered from the social determinants and stigma of HIV infection since early childhood.

Objectives: This study aimed to (1) describe demographic and clinical characteristics at the first appointment at adult care service following pediatric care of a cohort of Brazilian youths living with HIV since childhood; and (2) retrospectively address adherence and clinical variables in the last two years of pediatric follow-up.

Methods: Descriptive study.

Results: 41 consecutive patients referred to adult outpatient care from a pediatric HIV unit were enrolled, median age 19 years, and median lifetime CD4+ nadir 117 cell/mm³; 89% reported previous AIDS-defining conditions. At first laboratory assessment in adult care, only 46% had undetectable (<400 copies/ml) HIV viral load and the median CD4+ count was 250 cell/mm³.

Conclusion: Youths living with HIV at the transition from pediatric to adult care had poor treatment adherence, low lifetime CD4+ cell nadir, low CD4 cell count and detectable HIV viral load. Health care providers should closely monitor these adolescents in a youth friendly environment, prepared for open communication about all aspects of their health.

© 2019 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

^{*} Corresponding author: Rua Ferreira de Araujo, 789 SEAP-HCFMUSP, Sao Paulo, SP, CEP: 05428-002, Brazil. E-mail address: angela.freitas@hc.fm.usp.br (A.C. Freitas).

Introduction

HIV-infected patients who acquired the infection perinatally or in early childhood and survived to adult age have been transitioning to adult care in recent years. In Brazil, the first cohorts were referred to adult care in the late 2000's.¹ The complex period of transition to adult care is often associated with deterioration of clinical condition, which has been reported among youths with non-communicable chronic diseases, such as type I diabetes, cystic fibrosis, rheumatoid arthritis, congenital heart diseases, sickle cell anemia, and chronic renal disease.² Insufficient knowledge about their own health conditions, difficulties in self-care management, and treatment fatigue contribute to the hindering of disease control and increased morbidity and mortality during this transitional period.²

Youths living with HIV share several of these characteristics but also present particular features in dimensions that range from host-pathogen biologic interactions to the social determinants of the epidemic.³ Despite their young age, they are long-term hosts of the virus and therefore have prolonged exposure to antiretroviral therapy (ART). Adherence to therapy is often a challenge in this population, leading to impaired immune reconstitution and high occurrence of HIV-resistance mutations.^{3–7} Comorbidities such as cardiovascular diseases,⁸ metabolic conditions,^{9–12} and psychological or neurocognitive dysfunctions^{13–15} are also frequent in this population. Moreover, patients face the social stigma of HIV infection and remarkable challenges to lead their sexual lives,¹ in addition to family or social adversities, rendering this group particularly vulnerable to unfavorable outcomes in clinical care.^{3,16–18}

The influx of a large number of patients with such complex issues into adult HIV outpatient care may yield a significant burden to these specialized health services. A deeper understanding of the clinical characteristics and special needs of this group at transition to adult care could improve strategic allocation of resources aiming at a more successful disease control

In this study, we describe demographic and clinical characteristics of a cohort of 41 Brazilian youths at transition from pediatric to adult outpatient care.

All participants underwent a similar clinical management protocol, following guidelines of HIV treatment for children and adolescents issued by the Brazilian Ministry of Health. ^{19–21} These protocols have been sequentially adapted reflecting new scientific discoveries, incorporation of knowledge, and the increasing availability of ART drugs.

Methods

Study design and population

All consecutive youths living with HIV since childhood who were referred from pediatric to adult HIV outpatient clinics at our institution between January 2001 and December 2012 were enrolled. Since 2009, all patients transferred from pediatric care were individually reported with a complete medical history jointly revised by the pediatric and adult HIV clinicians.

Patients transferred between 2001 and 2009 were identified using administrative registries from adult and pediatric clinics to identify those with appointments at both facilities. Patients who, despite referral, did not have an actual appointment at the adult outpatient clinic were excluded from the analysis.

The adult outpatient clinic comprises adult HIV care as well as teaching services for medical students and fellows in Infectious Diseases, psychology, and social service, with approximately 3000 patients under care at the time these data were collected. Participants were referred from the pediatric HIV clinic located in a different facility of the same institution.

Study variables

Data were collected from pediatric and adult medical records, laboratories, and administrative systems. The researchers used standardized forms to collect the following information from the records: age at first visit to the adult care service (years); sex; race (categorized as white vs. others); orphanhood; type of caregiver; source of infection; schooling years; occupation (categorized as no occupation; student only; employed; student and employed); sexual health history (sexual activity status and previous or current pregnancies); results of laboratory tests (CD4+ counts and HIV viral load -VL) performed at the last visit and two years previous to the last visit at the pediatric follow-up and at the first visit to the adult outpatient care service (HIV VL considered undetectable when $<400 \text{ copies/ml} - 1.6 \log_{10}/\text{mL}$); lifetime CD4 + T cell nadir (CD4+ nadir); time interval from CD4+ nadir to the first visit of the adult outpatient care service [months]; treatment characteristics (time under ART [in years], current ART regimen, number of previous ART regimens [categorized as ≤4 or >4 previous regimens], number of daily doses and number of pills [categorized as <4 or ≥4 pills per day] in the current ART regimen); previous HIV genotypic resistance tests; AIDS-defining conditions according to CDC classification²² during pediatric follow-up; AIDS-associated morbidities, hospitalizations, and comorbidities during the 24 months prior to referral to adult care (recorded as reported in medical charts during routine care, as well as according to prescribed medical and behavioral interventions); treatment adherence (assessed using 1. medical charts; 2. missed appointments with healthcare provider, and 3. records of ART dispensation at pharmacy). Poor adherence was defined as having any of the following: description of inadequate/low adherence in medical records; ≥25% missed medical appointments; <85% dispensations of ART regimens from the institutional pharmacy at timely schedule (dispensations compatible with adequate ART uptake and restock).

Statistical analysis

Descriptive analysis was performed using frequencies and percentages, medians and interquartile ranges (IQR) for categorical and numeric variables, respectively. Incidence rates of AIDS-associated diseases and hospitalizations were calculated, as incidence density per 100 person-years, for the 24 months prior to admission in the adult care. Box plots were used to explore CD4+ counts and HIV VL according to adher-

Table 1 – Demographic characteristics of 41 HIV infected youths at transition to adult outpatient care at a teaching tertiary care hospital, Sao Paulo, Brazil, 2001–2012.

Variable	n (%)	Median (IQR)
Age – years		19 (18–20)
Female	22 (54)	
White	30 (73)	
Education - schooling years		12 (11-12)
MTCT	39 (95)	
Orphan	21 (51)	
Caregiver		
Family member	35 (85)	
Birth parent	17 (48)	
Foster parent	2 (6)	
Grandparent/other relative	16 (46)	
Institution	5 (12)	
None	1(2)	
Occupation		
Student	11 (27)	
Employee	10 (24)	
Student and employee	8 (20)	
None	12 (29)	

MTCT, Mother-to-child transmission; IQR, interquartile range.

ence to ART. All analyses were performed using Stata 14.2 (StataCorp. College Station, TX: StataCorp LP).

Ethical issues

Our Institutional Ethics Review Board approved this study (protocol 336.267). All patient identifiers were kept confidential.

Results

Forty-one youths reached adult care service between 2001 and 2012, 90% of them from 2009 to 2012. Main demographic characteristics are described in Table 1. A total of 39 (95%) participants were infected through mother-to-child transmission (MTCT) and 2 (5%) through blood transfusion, both before the age of five during leukemia treatment; both had remission of the hematologic disease reported in medical charts before HIV was diagnosed.

Clinical characteristics are summarized in Table 2. Of note, most participants had a previously impaired immune status, as shown by a low median lifetime CD4+ cell nadir and a high proportion of patients with pediatric CDC classification²² B2 or worse; median time between CD4 cell nadir and the first visit to the adult outpatient clinic was 25 months. In laboratory tests collected at the first visit at adult outpatient care, only 46% had undetectable HIV VL, median CD4+ count was 250 cell/mm³ (IQR 94-460), and 75% had CD4+ counts below 500 cell/mm³. Among the 25 (54%) youths with a detectable HIV VL, median HIV VL was 3.83 log₁₀ copies/mL (IQR 3.08-4.37). As shown in Fig. 1, the group with poor adherence had lower median CD4+ count and higher HIV VL compared to the group with good adherence. Metabolic conditions, dyslipidemia in particular, accounted for the most frequent comorbidities. Only one patient in the cohort had abnormal cognitive-motor

Table 2 – Clinical characteristics of 41 HIV infected youths at transition to adult outpatient care in a teaching tertiary care hospital, Sao Paulo, Brazil, 2001–2012.

CD4 count (cell/mm³) HIV viral load (copies/mL) Undetectable (<400 copies/mL) Detectable (≥400 copies/mL) Ignored Paediatric CDC AIDS-classification A1	Variable	n (%)	Median (IQR)
Undetectable (<400 copies/mL) 19 (46) Detectable (≥400 copies/mL) 21 (51) Ignored 1 (2) Paediatric CDC AIDS-classification A1 1 (2) A2 3 (7) A3 - B1 1 (2) B2 6 (15) B3 7 (17) C1 - C2 2 (5) C3 21 (51) Lifetime CD4 nadir (cells/mm³) 117 (30–237) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	CD4 count (cell/mm³)		250 (94–460)
Detectable (≥400 copies/mL) 21 (51) Ignored 1 (2) Paediatric CDC AIDS-classification 1 (2) A1 1 (2) A2 3 (7) A3 - B1 1 (2) B2 6 (15) B3 7 (17) C1 - C2 2 (5) C3 21 (51) Lifetime CD4 nadir (cells/mm³) 117 (30-237) Time between CD4 nadir and enrolment (months) 25 (9-69) AIDS-related diseases at pediatric transition period 3 (7) Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development <td>HIV viral load (copies/mL)</td> <td></td> <td>2.74 (1.59-3.92)</td>	HIV viral load (copies/mL)		2.74 (1.59-3.92)
Ignored	Undetectable (<400 copies/mL)	19 (46)	
Paediatric CDC AIDS-classification A1 1 (2) A2 3 (7) A3 - B1 1 (2) B2 6 (15) B3 7 (17) C1 - C2 2 (5) C3 21 (51) Lifetime CD4 nadir (cells/mm³) 117 (30–237) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 3 (7) Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	Detectable (≥400 copies/mL)	21 (51)	
A1	Ignored	1 (2)	
A2	Paediatric CDC AIDS-classification		
A3	A1	1 (2)	
B1 1 (2) B2 6 (15) B3 7 (17) C1 - C2 2 (5) C3 21 (51) Lifetime CD4 nadir (cells/mm³) 117 (30–237) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 3 (7) Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	A2	3 (7)	
B2 6 (15) B3 7 (17) C1	A3	-	
B3 7 (17) C1 - C2 2 (5) C3 21 (51) Lifetime CD4 nadir (cells/mm³) 117 (30–237) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 3 (7) Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Respitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	B1	1 (2)	
C1 C2 C2 C3 C3 C3 Lifetime CD4 nadir (cells/mm³) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis Herpes zoster Oral candidiasis Softy Esophageal candidiasis CMV meningoencephalitis Herpetic paraparesis Herpetic paraparesis CMV meningoencephalitis CMV meningoencephalitis Dyslipidemia Lipodystrophy Dilated cardiomyopathy Abnormal cognitive-motor development 117 (30–237) 117 (30–237) 117 (30–237) 117 (25 (9–69) 25 (9–69) 25 (9–69) 26 (9–69) 27 (12) 28 (12) 29 (2) 20 (2) 20 (2) 21 (2) 21 (3) 21 (2) 22 (9–69) 23 (7) 24 (2) 25 (9–69) 26 (9–69) 26 (9–69) 27 (12) 28 (12) 29 (2) 20 (12) 20 (13) 21 (2) 21 (2) 22 (2) 23 (3) 24 (34) 24 (34) 25 (9–69) 26 (9–69) 26 (9–69) 26 (9–69) 27 (12) 28 (9–69) 29 (2) 20 (17 (2) 20 (2) 20 (2) 20 (2) 20 (2) 20 (2) 20 (2) 20 (2) 21 (3) 21 (3) 21 (3) 22 (4) 23 (4) 24 (34) 25 (9–69) 26 (9–	B2	6 (15)	
C2 C3 C3 C1 (51) Lifetime CD4 nadir (cells/mm³) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis Herpes zoster Oral candidiasis SCMV meningoencephalitis Herpetic paraparesis Herpetic paraparesis CMV meningoencephalitis Herpetic paraparesis SCMV meningoencephalitis L(2) Herpetic paraparesis L(2) Recurrent pneumonia L(2) Hospitalization SCMV meningoencephalitis L(2) Hosp	В3	7 (17)	
C3 21 (51) Lifetime CD4 nadir (cells/mm³) 117 (30–237) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	C1	-	
Lifetime CD4 nadir (cells/mm³) Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis Herpes zoster 3 (7) Oral candidiasis 2 (5) CMV meningoencephalitis Herpetic paraparesis 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy Abnormal cognitive-motor development	C2	2 (5)	
Time between CD4 nadir and enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	C3	21 (51)	
enrolment (months) AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	Lifetime CD4 nadir (cells/mm³)		117 (30–237)
AIDS-related diseases at pediatric transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	Time between CD4 nadir and		25 (9–69)
transition period Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 3 (7) Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	, ,		
Tuberculosis 5 (12) Herpes zoster 3 (7) Oral candidiasis 3 (7) Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor development	AIDS-related diseases at pediatric		
Herpes zoster 3 (7) Oral candidiasis 3 (7) Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	transition period		
Oral candidiasis 3 (7) Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	Tuberculosis	` '	
Esophageal candidiasis 2 (5) CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	Herpes zoster	3 (7)	
CMV meningoencephalitis 1 (2) Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development		٠,,	
Hodgkin lymphoma 1 (2) Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	. 0	٠,,	
Herpetic paraparesis 1 (2) Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development		٠,	
Recurrent pneumonia 1 (2) Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development		٠,,	
Hospitalization 9 (22) Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development		٠,	
Comorbidities Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	•	` '	
Dyslipidemia 14 (34) Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	1	9 (22)	
Lipodystrophy 7 (17) Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development			
Dilated cardiomyopathy 3 (7) Abnormal cognitive-motor 1 (2) development	, .		
Abnormal cognitive-motor 1 (2) development		` '	
development		٠,,	
•		1 (2)	
Other 7 (17)	•		
	Other	7 (17)	

IQR, interquartile ranges; CDC, Centers for Disease Control and Prevention; CMV, cytomegalovirus.

development, reported as learning deficit and impaired selfcare in pediatric medical charts.

In the 24 months prior to transference to adult care, 34% of participants had been diagnosed with AIDS-defining conditions and 22% required hospitalization. Tuberculosis was the leading AIDS-associated disease, followed by herpes zoster and esophageal candidiasis, with incidence rates of 6.1, 3.7 and 2.4 per 100 person-years, respectively.

As described in Table 3, inadequate adherence was reported in 54% of medical records; 12 youths (29%) missed ≥25% appointments, and 24 youths (59%) had delayed ART dispensations from the institutional pharmacy. Altogether, using these different assessments, poor adherence was characterized in 73% of transitioning youths.

All cohort participants had long-term ART exposure. Most (78%) had received ART regimens containing less than three drugs early in the course of their treatment. In addition, HIV genotypic tests were performed for 29% of the youths during




Fig. 1 – Box plots of (a) HIV viral load (log₁₀ copies/ml) and (b) CD4+ cell count (cells/mm³) measured at the first visit to the adult outpatient care service, according to adherence status during pediatric care service.

Table 3 – Antiretroviral treatment characteristics of 41 HIV infected youths at transition to adult outpatient care in a teaching tertiary care hospital, Sao Paulo, Brazil, 2001–2012.

Variable	n (%)	Median (IQR)
Time on ART – years		15 (12–17)
Current ART regimen		
None	2 (5)	
2 NNRTI	2 (5)	
2 NRTI + NNRTI	12 (29)	
2 NRTI + PI	17 (41)	
Others	8 (20)	
Current treatment dosing		
q.d.	2 (5)	
b.i.d.	37 (95)	
Number of pills in current		6 (5–8)
ART regimen		
Number of previous ART		4 (3–6)
regimens		
Received ART regimen with	32 (78)	
<3 active drugs		
Underwent HIV genotypic	12 (29)	
test at pediatric		
transition period		
ART regimen change due to	10 (83)	
drug resistance		
Adherence		
Poor adherence reported	22 (54)	
in medical charts		
≥25% missed medical	12 (29)	
appointments		
<85% of timely ART	24 (59)	
withdrawal		
Any indication of poor	30 (73)	
adherence ^a		

IQR, interquartile ranges; NRTI, nucleoside and nucleotide reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; ART, antiretroviral therapy; q.d, once daily; b.i.d, twice daily.

^a Presence of either inadequate adherence in medical records, ≥ 25% missed medical appointments or <85% timely antiretroviral dispensations from the institutional pharmacy.</p>

the last 24 months at pediatric service, triggering modification in ART regimens for 83% of them.

As an important part of youth health, 59% of 34 participants reported being sexually active and four (10%) of them

were either pregnant or had partners expecting a child at the moment of transference to adult care service.

Discussion

In this study, we present demographic and clinical characteristics of a cohort of youths infected with HIV early in childhood (MTCT or blood transfusion) at the transition to adult HIV care as well as HIV VL and CD4+ cell count/mm³ at first assessment in the adult care service. Having acquired HIV at the beginning of the Brazilian HIV epidemic, this cohort was exposed to the evolving national recommendations for HIV treatment that guarantees free access to ART through the public health care system (Sistema Unico de Saúde, SUS) since 1992. 19–21 As such, they were frequently exposed to regimens currently considered suboptimal, to drugs that are more likely to induce metabolic adverse events or to medications not adapted to children's taste. Moreover, HIV VL tests were not available for clinical monitoring until late in their follow-up. 19–21

Poor adherence during the last 24 months at pediatric care was frequent, as in other Brazilian and foreign cohorts of young adults living with HIV since childhood, 18,23–28 and discordant of the Swedish single-center cohort, that reports poor adherence by only 12%. This highlights the expected difficulties in the clinical management of this special group of patients.

At their first laboratory tests performed in adult care, youths often exhibited uncontrolled disease, as seen by low CD4+ cell counts and a high proportion (54%) of patients with detectable HIV VL, similarly to reports from other cohorts of transitioning youths. ^{7,28–30}

Dyslipidemia was the most common comorbidity in this population. It could be attributed to metabolic effects of ART and/or to the inflammatory status seen in chronic AIDS, or, alternatively, it could be associated with a less healthy diet and poor exercise habits, as shown previously for this population when still at pediatric care. 31,32 Aiming to prevent cardiovascular diseases, our findings highlight the need to prioritize ART drugs with a better metabolic profile provided that they are active to each particular patient. Whenever possible, this should be combined with continuous counseling for healthier diet and exercise. Although lifestyle modifications can be challenging, nutritional counseling and promotion of physical activities by skilled personnel could be important tools in the comprehensive care of this population.

The high frequency of ART modifications after HIV genotyping tests and high number of pills in the current ART regimen support the hypothesis that these youths had a bad ART resistance profile at transition to adult care, as has been previously reported. 3,4,6,7,30 In addition, they presented poor immune reconstitution as compared to participants from the IPEC cohort,³³ a Brazilian cohort including adults aged 18 and over at the beginning of their HIV treatment. Our cohort of youths had lower median CD4+ cell counts compared to the subgroup in IPEC cohort that initiated treatment in the same period (2009-2012), i.e. 250 cell/mm³ (IQR 94-460) versus 310 cell/mm³ (IQR 108-551). Furthermore, we observed higher incidence of tuberculosis (6.10/100 person-years) during the two years prior to transference to adult care, as compared to a cohort of 599 adult patients followed at the same institution (1.47/100 person-years).³⁴ Except for higher incidence of tuberculosis, AIDS-associated diseases in our cohort are consistent with findings from the perinatally infected youths in the IMPAACT study,³⁵ in which the most frequently reported morbidities were herpes zoster, oropharyngeal candidiasis, esophageal or pulmonary candidiasis, and pneumonia. Interestingly, despite their low CD4+ cell count, youths in our cohort did not present with cerebral toxoplasmosis or Pneumocystis jiroveci pneumonia, commonly seen in adults with impaired immunity and leading causes of AIDS-associated illness in the IPEC cohort.33

Social and household characteristics may add difficulties to the care and wellbeing of these youths. Half of them had lost both parents, 12% were raised in institutions and others were raised by grandparents, who are expected to decrease their support possibilities as they age. As reported by Acree, ²⁶ adult health care providers should encourage a slow transition from a social support network to autonomous self-care, avoiding an abrupt break in practical and emotional assistance.

Median attained education of 12 schooling years reflects that most youths complete middle school education, but only half of them reach technical or university-level courses. Our patients had low participation in the workforce (44% employed) and a high proportion (30%) of the cohort was neither employed nor studying. This could reflect the current economic crisis in Brazil, further complicated by frequent absenteeism related to health care appointments.

Most patients in our cohort were sexually active. Sexual activity could be a challenge for these youths. Studies about pregnancy in HIV-infected adolescents and young adults have shown that perinatally infected pregnant youths have higher rates of unintended pregnancies, ³⁶ lower adherence to ART, ^{36,37} and lower rates of HIV disclosure when compared to youths infected sexually. ³⁸ Thus, one could suggest the adult health care team to be particularly keen to implement an easy channel to talk about sexuality and family planning with these youths.

Accurate evaluation of treatment adherence is a challenge in clinical as well as research settings.³⁹ A strength in our study was the assessment of adherence using a combined evaluation of medical charts, ART dispensation at the institutional pharmacy, and missed appointments with the healthcare providers.

A limited sample size should be considered as a potential weakness of our study, reflecting that MTCT is a relatively rare event in our setting, potentially due to testing and treatment strategies offered to pregnant women in the Brazilian Aids program since 1996. Additionally, the small number or participants in our study also suggests that few HIV-infected children have survived over the first years of the HIV epidemic and reached adult care. Moreover, due to the retrospective nature of the study we failed to collect information on sexual orientation, drug abuse, or psychosocial distress since such information was often lacking or incomplete in medical charts. Finally, the fact that our study addressed patients from a single institution restricts generalizability of our findings. Nevertheless, our study describes one of the first cohorts of perinatally infected youths transitioning to adult care in Latin America, and highlights patient characteristics that are relevant to clinical management in this population. Future multicenter studies with larger sample size and longitudinal follow-up are warranted to better identify predictors of clinical outcomes in this vulnerable population.

In conclusion, most youths living with HIV since early childhood in our Brazilian cohort reached adult outpatient care service with poor adherence to ART, low CD4+ cell counts and detectable HIV VL. A third of them had Aids-associated illnesses in the last two years of pediatric follow-up. Based on our results as well as on findings from other cohorts of young adults living with HIV since early childhood, we recommend that adult health care providers should closely monitor these transitioning youths. Comprehensive care should be offered with a multi-professional team, implementing protocols to track treatment failure, stimulate healthier lifestyles, encourage active participation of caregivers in the transition process, afford psychological and social support, and develop a youth-friendly environment prepared for open communication about all aspects of youth's health.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

The authors kindly thank Delsa Nagata, Camila Piccone, Elza Habe and Cleide Maluvayshi for their valuable help with data collection.

REFERENCES

- 1. Machado DM, Galano E, de Menezes Succi RC, Vieira CM, Turato ER. Adolescents growing with HIV/AIDS: experiences of the transition from pediatrics to adult care. Braz J Infect Dis. 2016;20:229–34, http://dx.doi.org/10.1016/j.bjid.2015.12.009.
- Campbell F, Biggs K, Aldiss SK, et al. Transition of care for adolescents from paediatric services to adult health services.

- Cochrane Database Syst Rev. 2016, http://dx.doi.org/10.1002/14651858.CD009794.pub2.
- Agwu AL, Fairlie L. Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. J Int AIDS Soc. 2013;16:18579, http://dx.doi.org/10.7448/ias.16.1.18579.
- de Mulder M, Yebra G, Navas A, et al. High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain. PLoS One. 2012;7:e52155, http://dx.doi.org/10.1371/journal.pone.0052155.
- Bailey H, Cruz MLS, Songtaweesin WN, Puthanakit T. Adolescents with HIV and transition to adult care in the Caribbean, Central America and South America, Eastern Europe and Asia and Pacific regions. J Int AIDS Soc. 2017;20:50–9, http://dx.doi.org/10.7448/ias.20.4.21475.
- Judd A, Lodwick R, Noguera-Julian A, et al. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. HIV Med. 2017;18:171–80, http://dx.doi.org/10.1111/hiv.12411.
- Van der Linden D, Lapointe N, Kakkar F, et al. The young and the resistant: hiv-infected adolescents at the time of transfer to adult care. J Pediatric Infect Dis Soc. 2013;2:382–5, http://dx.doi.org/10.1093/jpids/pis106.
- Lipshultz SE, Williams PL, Wilkinson JD, et al. Cardiac status
 of children infected with human immunodeficiency virus
 who are receiving long-term combination antiretroviral
 therapy: results from the Adolescent Master Protocol of the
 Multicenter Pediatric HIV/AIDS Cohort Study. JAMA Pediatr.
 2013;167:520–7, http://dx.doi.org/10.7448/ias.16.1.18597.
- Blazquez D, Ramos-Amador JT, Sainz T, et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis. 2015;15:119, http://dx.doi.org/10.1186/s12879-015-0853-8.
- Fortuny C, Deya-Martinez A, Chiappini E, Galli L, de Martino M, Noguera-Julian A. Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. Pediatr Infect Dis J. 2015;34:S36–43, http://dx.doi.org/10.1097/INF.000000000000663.
- Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc. 2013;16:18600, http://dx.doi.org/10.7448/ias.16.1.18600.
- Schtscherbyna A, Pinheiro MF, Mendonca LM, et al. Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents. Int J Infect Dis. 2012;16:e872–8, http://dx.doi.org/10.1016/j.ijid.2012.07.019.
- 13. Nichols SL, Chernoff MC, Malee K, et al. Learning and memory in children and adolescents with perinatal HIV infection and perinatal HIV exposure. Pediatr Infect Dis J. 2016;35:649–54, http://dx.doi.org/10.1097/inf.000000000001131.
- Cohen S, Caan MW, Mutsaerts HJ, et al. Cerebral injury in perinatally HIV-infected children compared to matched healthy controls. Neurology. 2016;86:19–27, http://dx.doi.org/10.1212/wnl.000000000002209.
- Kacanek D, Angelidou K, Williams PL, Chernoff M, Gadow KD, Nachman S. Psychiatric symptoms and antiretroviral nonadherence in US youth with perinatal HIV: a longitudinal study. AIDS. 2015;29:1227–37, http://dx.doi.org/10.1097/QAD.0000000000000697.
- Cruz ML, Bastos FI, Darmont M, Dickstein P, Monteiro S. The moral careerof perinatally HIV-infected children: revisiting Goffman's concept. AIDS Care. 2015;27:6–9, http://dx.doi.org/10.1080/09540121.2014.940270.
- de Paula CC, Cabral IE, Souza IE. The (un)said about AIDS in the quotidian transition from childhood to the adolescence. Rev Bras Enferm. 2011;64:658–64.

- Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS. 2010;24:97–104, http://dx.doi.org/10.1089/apc.2009.0198.
- Ministério da Saúde, Secretaria de Ações Básicas de Saúde. Recomendações para prevenção e controle da infecção pelo vírus HIV (SIDAAIDS) no Brasil. Brasília: Ministério da Saúde; 1987
- 20. Ministério da Saúde, Secretaria de Políticas de Saúde, Coordenação Nacional de DST e AIDS. Guia de Tratamento Clinico da Infecção pelo HIV em Crianças. Brasília: Ministério da Saúde; 2001.
- 21. Ministério da Saúde, Secretaria de Vigilância em Saúde, Programa Nacional de DST e AIDS. Recomendações para terapia antirretroviral em crianças infectadas pelo HIV. Brasília: Ministério da Saúde; 2009.
- CDC. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43:1–10 https://www.cdc.gov/mmwr/preview/mmwrhtml/00032890.htm
- Kakkar F, Van der Linden D, Valois S, et al. Health outcomes and the transition experience of HIV-infected adolescents after transfer to adult care in Quebec, Canada. BMC Pediatr. 2016;16:109, http://dx.doi.org/10.1186/6s12887-016-0644-4.
- Buchanan AL, Montepiedra G, Sirois PA, et al. Barriers to medication adherence in HIV-infected children and youth based on self- and caregiver report. Pediatrics. 2012;129:e1244–51, http://dx.doi.org/10.1542/peds.2011-1740.
- Agwu AL, Lee L, Fleishman JA, et al. Aging and loss to follow-up among youth living with human immunodeficiency virus in the HIV Research Network. J Adolesc Health. 2015;56:345–51, http://dx.doi.org/10.1016/j.jadohealth.2014.11.009.
- Acree ME. Transition of care for youth with HIV. Pediatr Ann. 2016;46:e198–202, http://dx.doi.org/10.3928/19382359-20170424-02.
- Westling K, Náver L, Vesterbacka J, et al. Transition of HIV-infected youths from paediatric to adult care, a Swedish single-centre experience. Infect Dis. 2016;48:449–52, http://dx.doi.org/10.3109/23744235.2016.1143964.
- Ryscavage P, Macharia T, Patel D, Palmeiro R, Tepper V. Linkage to and retention in care following healthcare transition from pediatric to adult HIV care. AIDS Care. 2016:1–5, http://dx.doi.org/10.1080/09540121.2015.1131967.
- Judd A, Collins IJ, Parrott F, et al. Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK. J Int AIDS Soc. 2017;20:71–80, http://dx.doi.org/10.7448/ias.20.4.21577.
- Cordova E, Yanez J, Rodriguez Ismael CG. Safety and efficacy
 of antiretroviral therapy in perinatally HIV-1 infected patients
 following transition to an adult HIV-care hospital with
 virological failure in Buenos Aires, Argentina. Enferm Infecc
 Microbiol Clin. 2015;33:134–5,
 http://dx.doi.org/10.1016/j.eimc.2014.05.005.
- Tanaka LF, Latorre MR, Silva AM, Konstantyner TC, Peres SV, Marques HH. High prevalence of physical inactivity among adolescents living with HIV/Aids. Rev Paul Pediatr. 2015;33:327–32, http://dx.doi.org/10.1016/j.rpped.2014.12.003.
- Tanaka LF, Latorre MR, Silva AM, Konstantyner TC, Mendes EC, Marques HH. Poor diet quality among Brazilian adolescents with HIV/AIDS. J Pediatr (Rio J). 2015;91:152–9, http://dx.doi.org/10.1016/j.jped.2014.06.007.
- Coelho L, Cardoso SW, Amancio RT, et al. Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One. 2014;9:e98666, http://dx.doi.org/10.1371/journal.pone.0098666.

- Casseb J, Fonseca LA, Medeiros LA, et al. Tuberculosis among HIV-1-infected subjects in a tertiary out-patient service in Sao Paulo city, Brazil. Rev Inst Med Trop Sao Paulo. 2012;54:257–9, http://dx.doi.org/10.1590/S0036-46652012000500004.
- 35. Mirani G, Williams PL, Chernoff M, et al. Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy. Clin Infect Dis. 2015;61:1850–61, http://dx.doi.org/10.1093/cid/civ687.
- Sheth SS, Coleman J, Cannon T, et al. Association between depression and nonadherence to antiretroviral therapy in pregnant women with perinatally acquired HIV. AIDS Care. 2015;27:350–4,
 - http://dx.doi.org/10.1080/09540121.2014.998610.

- Byrne L, Thorne C, Foster C, Tookey P. Pregnancy outcomes in women growing up with perinatally acquired HIV in the United Kingdom and Ireland. J Int AIDS Soc. 2014;17:19693, http://dx.doi.org/10.7448/ias.17.4.19693.
- Badell ML, Kachikis A, Haddad LB, Nguyen ML, Lindsay M.
 Comparison of pregnancies between perinatally and sexually HIV-infected women: an observational study at an urban hospital. Infect Dis Obstet Gynecol. 2013;2013:301763, http://dx.doi.org/10.1155/2013/301763.
- Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS. 2014;28:1945–56, http://dx.doi.org/10.1097/QAD.00000000000316.